Get startedLog in
    Picture of Bayer AG logo

    BAYN — Bayer AG News Story

    0.000.00%
    de flag iconLast trade - 00:00
    HealthcareAdventurousLarge CapMomentum Trap
    All News

    Brief: FDA Accepts Bayer’S Supplemental New Drug Application For Kerendia For Adults With Chronic Kidney Disease Without Diabetes

    Picture of Bayer AG logoBayer AG
    08/10/2026 07:34
    BRIEF-FDA Accepts Bayer’S Supplemental New Drug Application For Kerendia For Adults With Chronic Kidney Disease Without Diabetes
    Oct 8 (Reuters) - Bayer AG BAYGn.DE:
    • U.S. FDA ACCEPTS BAYER’S SUPPLEMENTAL NEW DRUG APPLICATION FOR KERENDIA® (FINERENONE) TO TREAT ADULTS WITH CHRONIC KIDNEY DISEASE (CKD) WITHOUT DIABETES
    • BAYER AG - KERENDIA MEETS PRIMARY ENDPOINT, REDUCES KIDNEY FUNCTION DECLINE VERSUS PLACEBO
    • BAYER AG - KERENDIA REDUCES RISK OF COMPOSITE KIDNEY-CARDIOVASCULAR ENDPOINT VERSUS PLACEBO
    Source text: ID:nBw48SqG2a
    Further company coverage: [BAYGn.DE]

     (Gdansk Newsroom)
     ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

    Recent news on Bayer AG

    See all news